[vc_column][prkwp_styled_title prk_in=”Canadian Reimbursement and Forecasting Timelines (CRaFT) Report” align=”Center” font_weight=”700″ text_color=”#ffffff” title_size=”h1″ margin_bottom=”6px” css_animation=”right-to-left” css_delay=”20″ custom_css=”text-shadow: 6px 6px 9px rgb(0, 0, 0), 5px 5px 31px rgb(0, 0, 0);”][prkwp_spacer size=”25″][prkwp_styled_title prk_in=”October 2021 Update” align=”Center” font_weight=”300″ text_color=”#ffffff” title_size=”h3″ margin_bottom=”6px” css_animation=”right-to-left-faster” css_delay=”28″ custom_css=”text-shadow: 6px 6px 9px rgb(0, 0, 0), 5px 5px 31px rgb(0, 0, 0);”][/vc_column]
[vc_column][prk_line color="#efefef"][/vc_column]
[vc_column width=”1/2″ col_width=”80″ css_animation=”hook_fade_waypoint” css_delay=”12″ bg_color=”#f9f9f9″][prkwp_spacer size=”45″][prkwp_service name=”WHY DO YOU NEED THIS REPORT?” text_color=”#12b2cb” icon_type=”custom_image” align=”center” text_align=”hook_left_align” icon_up_color=”#ffffff” el_class=”text-light”][vc_column_text]

The Canadian Reimbursement and Forecasting Timelines (CRaFT) Report October 2021 update is a 100+ page PowerPoint resource complete with analysis and insights from trusted industry experts.

MORSE analyzed Canadian market access data to create key reimbursement metrics. The Report can support any organization that is planning a Canadian launch by providing critical timeline insights on the public market reimbursement process – from HTA submission to provincial listing.

[/vc_column_text][prkwp_spacer size=”45″][/vc_column][vc_column width=”1/2″ bg_image=”4097″][vc_column_text][/vc_column_text][/vc_column]

[vc_column][prk_line color="#efefef"][/vc_column]
[vc_column width=”1/2″ col_width=”90″ css_animation=”hook_fade_waypoint” css_delay=”” bg_image=”6498″][prkwp_spacer size=”90″][vc_column_text][/vc_column_text][prkwp_spacer size=”45″][/vc_column][vc_column width=”1/2″ col_width=”80″ bg_color=”#29b9cf”][prkwp_spacer size=”45″][prkwp_service name=”WHAT DOES THE REPORT INCLUDE?” text_color=”#13294b” icon_type=”custom_image” align=”center” text_align=”hook_left_align” icon_up_color=”#ffffff” el_class=”text-light”][vc_column_text css_animation=”hook_fade_waypoint”]

  • Analysis of pCPA process phase timelines
  • Negotiation trends
  • Provincial time-to-listing trends and market access timelines
  • Sub-analysis of data with stratification by oncology & non-oncology
  • CADTH and pCPA volume & Timeline metrics
  • pCPA Developments

The Report focuses on metrics from 2020 but also provides relevant comparisons to 2019 and 2018 to identify trends. In addition, it contains formulary listing information from 2019 & 2020 pCPA Completed Negotiations (current as of June 30, 2021).

[/vc_column_text][prkwp_spacer size=”45″][/vc_column]

[vc_column][prk_line color="#efefef"][/vc_column]
[vc_column col_width=”80″ css_animation=”hook_fade_waypoint” css_delay=”12″][prkwp_spacer size=”120″][prkwp_service name=”FEEDBACK ON THIS REPORT” text_color=”#12b2cb” icon_type=”custom_image” align=”center”][prk_testimonials category="craft" color="#ffffff" show_controls="arrows" delay="13000"][prkwp_spacer size=”60″][/vc_column]
[vc_column width=”1/2″ col_width=”80″ css_animation=”hook_fade_waypoint” css_delay=”16″ bg_color=”#f9f9f9″][prkwp_spacer size=”60″][vc_column_text]

NEW! CRaFT ONCOLOGY AND BIOSIMILAR SUB-REPORT

[/vc_column_text][vc_column_text]

Designed to accompany the MORSE CRaFT Report, the Oncology and Biosimilar Sub-Report provides a thorough analysis of Canadian market access timelines for IV oncology drugs compared to oral oncology drugs and the most up-to-date listing data for biosimilar drugs.

[/vc_column_text][prkwp_spacer size=”35″][vc_raw_html]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[/vc_raw_html][prkwp_spacer size=”35″][prkwp_spacer size=”108″][/vc_column][vc_column width=”1/2″ col_width=”80″ el_id=”craftform”][prkwp_spacer size=”60″][prkwp_service name=”For further information on content and pricing, please complete the form below.” text_color=”#13294b” icon_type=”custom_image” align=”center” text_align=”hook_left_align”][vc_column_text]

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.

[/vc_column_text][prkwp_spacer size=”20″][vc_column_text][forminator_form id="5920"][/vc_column_text][vc_raw_html]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[/vc_raw_html][/vc_column]

[vc_column][/vc_column]

Canadian Reimbursement and Forecasting Timelines Report, October 2021 Update